INTRODUCTION
Neurogenic lower urinary tract dysfunction (NLUTD) affects the majority of patients with spinal cord injury (SCI). The main concern in these patients is renal damage as a result of high detrusor storage and voiding pressures, 1 which used to be the most common cause of mortality in SCI. 2 High detrusor pressures result from detrusor overactivity or low bladder compliance, often combined with detrusor-sphincter-dyssynergia. 3 Antimuscarinic drugs have therefore become the first-line treatment for alleviating neurogenic detrusor overactivity (NDO). 3, 4 The control of storage and voiding detrusor pressures has resulted in lower mortality rates from urological causes in SCI patients. 5 The efficacy and safety of antimuscarinic drugs, such as oxybutynin, trospium chloride, tolterodine and propiverine, for the long-term treatment of NDO is well established. 4, 6 The antimuscarinic treatment of NDO in SCI patients lasts commonly lifelong, and thus compliance with therapy is an important issue. Unfortunately, SCI patients tend to require higher doses of antimuscarinic drugs than those with idiopathic detrusor overactivity, 4 which in turn may lead to more or more severe adverse events 7 and consequently to abortion of treatment. 4, 6, 8 Solifenacin is a once daily oral antimuscarinic drug with a high affinity for the M 3 muscarinic receptor in the bladder, which is regarded to be the main mediator of detrusor contractility. 9 Solifenacin has been reported to be more effective (quality of life, patient reported cure, incontinence and urgency episodes) and cause fewer adverse events and thus fewer withdrawals than other antimuscarinic drugs in patients with idiopathic overactive bladder. 10 To date, there is no data on the efficacy of solifenacin in the treatment of NDO as a result of SCI. In a study with patients suffering from multiple sclerosis, solifenacin significantly improved voiding frequency, severity of urgency and incontinence. 11 However, no urodynamic data had been reported. We therefore investigated the urodynamic effects of solifenacin treatment for NDO in patients with SCI.
MATERIALS AND METHODS
This retrospective study was approved by the local Ethics Committee, and all patient data were made anonymous and kept confidential. We certify that all applicable institutional and governmental regulations concerning the ethical use of the data were followed during the course of this research.
The case histories of all patients being treated with solifenacin (Vesicare, Astellas Pharma, Wallisellen, Switzerland) for NLUTD following SCI and undergoing urodynamic examination at our institution between January 2008 and March 2012 were reviewed. A total of 41 patients were identified.
The patient characteristics, type of NLUTD, bladder diary details (includng number of incontinence pads and urinary tract infections), drugs with known relevant impact on detrusor function and urodynamic data (bladder capacity, maximum detrusor pressure during the storage phase, detrusor compliance and reflex volume) were collected. Patients were categorized as being at risk of renal damage if maximum detrusor pressure was 440 cm H 2 O or detrusor compliance was o20 ml cm À1 H 2 O. 12 Urodynamic examination was performed with the patient in supine position. An 8-French transurethral double-lumen catheter and a 14-French indwelling rectal catheter were used for the measurement of intravesical and rectal pressure, respectively. The bladder was filled with sterile 0.9% saline solution at body temperature with a filling rate of 20 ml min À1 . Intravesical and rectal pressure were measured by Statham pressure transducers, and the data were recorded by a standard urodynamic software (Medical Measurement Systems, Gladbeck, Germany). Suprapubic tapping was used as a standard provocative maneuver at the end of the examination. Measurement and evaluation of the urodynamic parameters were performed according to the current International Continence Society standards. 13 The following urodynamic parameters were evaluated: bladder capacity, detrusor compliance, maximum detrusor pressure during the storage phase and reflex volume, if applicable.
The data were calculated and presented as the median and the interquartile range (IQR). The differences between independent and dependent samples were tested with the Mann-Whitney U and the Wilcoxon signed-rank test, respectively. The w 2 and Fisher's exact test were used to test differences in the observed frequency distribution between groups. Statistical analyses were performed using the SPSS software (version 18.0.3, IBM, Somers, NY, USA). A P-value of o0.05 was considered significant.
RESULTS
The data of 41 SCI patients being treated with solifenacin for NDO were screened for exclusion criteria. Six patients were excluded: three were using suprapubic catheters, two had additionally received botulinum toxin injections into the detrusor muscle and one had been lost to follow-up.
The etiology of SCI in the remaining 35 patients (25 males and 7 females) was predominately trauma (n ¼ 30, 85.7%). There were three patients with myelomeningocele, as well as one patient each with vascular and uncertain etiology. There were 4 tetraplegic and 31 paraplegic patients. The majority of patients (n ¼ 32, 91.4%) suffered from suprasacral lesions. SCI was complete in 15 and incomplete in 20 patients, respectively. All patients suffered from urodynamically confirmed NDO. There were no statistically significant differences between the urodynamic values of the traumatic and the nontraumatic SCI patients (P40.2) nor between values of the patients with prior antimuscarinic treatment and those without (P40.1).
Thus, the data were pooled for analysis and presentation (Table 1) . The majority of patients (n ¼ 22, 62.9%) suffered from NDO despite oral antimuscarinic medication before solifencain treatment: tolterodine (n ¼ 14), oxybutynin (n ¼ 6), darifenacin (n ¼ 1) and trospium chloride (n ¼ 1). Most patients (n ¼ 32, 91.4%) used intermittent catheterization for bladder evacuation, whereas three patients emptied the bladder with the help of the Valsalva maneuver.
The indications for solifenacin treatment initiation are listed in Table 2 . Solifenacin treatment was initiated 7.3 years (median, IQR 2.7-22.0 years) after SCI. The median age of the patients at the treatment initiation was 44.9 years (IQR 34.4-56.3 years). The majority of patients (n ¼ 33, 94.3%) was taking 10 mg solifenacin daily, two were taking 5 mg. The most recent follow-up data was collected 13.1 months (median, IQR 6.1-19.5 months) after treatment initiation. In all, 4 patients were also taking pregabalin (n ¼ 3) or gabapentin (n ¼ 1), and 10 patients were taking antispastic medication: baclofen (n ¼ 4), tizanidine (n ¼ 2) or both (n ¼ 1). No further medication with antimuscarinic activity was taken. The dosage of these drugs remained stable during the follow-up period. Solifenacin treatment resulted in significant improvements in all urodynamic parameters (Figure 1 ): bladder capacity þ 30.0 ml (median, IQR 0.0-69.0 ml), maximum detrusor pressure À7.0 cm H 2 O (median, IQR À17.0 to À1.0 cm H 2 O), reflex volume þ 62.5 ml (median, IQR 12.5-101.0 ml) and detrusor compliance þ 25.0 ml cm À1 H 2 O (median, IQR À1.0 to 50.0 ml cm À1 H 2 O). Furthermore, fewer patients presented with a risk of renal damage (6 vs 13 based on maximum detrusor pressure, 8 vs 11 based on detrusor compliance; Table 1 ). However, these differences were not significant (P40.1). There was no difference between the number of absorptive pads used or the daily frequency of intermittent catheterization for bladder evacuation before and under solifenacin treatment, and the number of patients suffering from incontinence remained virtually unchanged (16 vs 19; Table 1 ).
Four of the six patients, who received solifenacin because of intolerable adverse events of their current antimuscarinic drug, reported no adverse events under solifenacin. However, three patients, who had not complained of antimuscarinic drug adverse events previously, experienced adverse events under solifenacin. In one of these patients, adverse events were intolerable and resulted in treatment termination. The documented adverse events of solifenacin were: dry mouth (n ¼ 2),and fatigue (n ¼ 2); in one patient adverse events were not specified.
In 11 patients (31.4%), solifenacin treatment was discontinued: in 6 (17.1%) and 2 patients (5.7%) as a result of insufficient efficacy and intolerable adverse events, respectively. Of these patients, two received other antimuscarinic drugs, four were treated by botulinum toxin injection in the detrusor and one received electro-motive drug administration. In another patient, neuromodulation was recommended. Three patients had terminated solifenacin medication without further explanation.
DISCUSSION
This is the first study reporting on the urodynamic effects of solifenacin treatment for NDO in patients with SCI. Solifenacin treatment resulted in significant improvements in all urodynamic parameters: detrusor compliance increased by 66%, reflex volume by 39%, bladder capacity by 6% and maximum detrusor pressure decreased by 39%. Furthermore, fewer patients presented with a risk of renal damage or incontinence, although these trends did not reach statistical significance. The majority of patients (69%) continued solifenacin treatment.
To the best of our knowledge, there is no published manuscript describing the urodynamic effects of solifenacin in patients with NLUTD due to SCI. In the only study including some patients with NDO, bladder capacity at the time when patients felt a strong desire to void was significantly increased (by 27% from 297 to 378 ml) in 52 female patients with overactive bladder symptoms, who were treated with 5 mg of solifenacin. 14 However, intravesical pressure was not significantly decreased in these patients. Unfortunately, the results were not presented separately for patients with overactive bladder symptoms of neurogenic and idiopathic origin, respectively. In another study evaluating the effects of solifenacin on patients with NDO as a result of multiple sclerosis, no urodynamic data were evaluated. 11 Studies evaluating the urodynamic effects of solifenacin in idiopathic detrusor overactivity, most commonly summarized under 'overactive bladder syndrome' , are rare. This may at least partially be the result of the fact that overactive bladder syndrome in nonneurogenic patients is a clinical diagnosis, not involving urodynamic measurements. 15 In one of the few urodynamic-based studies in patients suffering from overactive bladder syndrome, Lowenstein et al. 16 have reported a 41% increase in bladder capacity in 10 women treated with 10 mg of solifenacin. In contrast, Hsiao et al. 17 have not observed any changes in detrusor pressure at maximal flow rate or bladder capacity at strong desire to void in 21 female patients with overactive bladder syndrome under solifenacin treatment.
In this study, fewer patients (12 vs 17) presented with a risk of renal damage under solifencain treatment. Although this difference, most probably as a result of the limited number of patients included, was not significant, the data demonstrated that protection of renal function, the ultimate goal of NLUTD treatment in patients with SCI, can be achieved by solifenacin in a substantial number of patients. As solifenacin was administered as a second-line treatment in the majority of patients (n ¼ 22, 63%), solifenacin was effective in a substantial number of patients even though other antimuscarinic medication had failed previously.
In this study, solifenacin treatment did not reduce the number of patients suffering from incontinence, the number of absorptive pads used or the daily frequency of intermittent catheterization for bladder evacuation. However, in NLUTD after SCI, incontinence is often multifactorial and is not always caused by NDO alone. Therefore, even after effective treatment of NDO by solifenacin, incontinence may persist. Furthermore, clinical symptoms are not reliable for the assessment of severity of NDO or the risk of renal damage. Regular urodynamic evaluation is warranted to ensure prevention of upper urinary tract damage. 4, 18 In this study, two patients (6%) discontinued solifenacin treatment as a result of intolerable adverse events. Four of the six patients (67%), who had received solifenacin because of intolerable adverse events of their previous antimuscarinic drug, reported no adverse events under solifenacin. The recorded adverse events were dry mouth and fatigue. The percentage of treatment discontinuation as a result of intolerable adverse events reported in the literature is similar to our results for 10 mg solifencain. 11, 19, 20 Gastrointestinal (dry mouth and constipation) and eye disorders (blurred vision) were the most commonly reported side effects. 20 The abortion rate in our study was very similar to the one reported by van Rey et al. 11 in patients suffering from NDO following multiple sclerosis.
The urodynamic results of antimuscarinic treatment of NDO in patients with SCI vary widely between studies. As all studies differ significantly regarding inclusion and exclusion criteria and duration of treatment, merely head-to-head comparisons can reliably compare the efficacy and tolerability of different antimuscarinic drugs. However, our results compare favorably to previously published data in this cohort of patients. 6 The limited number of patients and the retrospective design pertain to the limitations of this study. However, this is the first investigation of the urodynamic effects of solifenacin treatment in patients suffering from NDO following SCI. As solifenacin is not licensed for the treatment of NDO, we exclusively use the substance as a second-line treatment, which may have resulted in an underestimation of its effectiveness. Based on the encouraging results of our study concerning both effectiveness and tolerability, prospective randomized placebo-controlled studies of solifenacin as a first-line treatment for NDO after SCI should be conducted.
DATA ARCHIVING
There were no data to deposit.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
